Julia K Tietze1, Daniela Angelova2, Markus V Heppt2, Markus Reinholz2, William J Murphy3, Michael Spannagl4, Thomas Ruzicka2, Carola Berking2. 1. Department of Dermatology and Allergy, University Hospital Munich (LMU), Frauenlobstr. 9-11, 80337 Munich, Germany. Electronic address: Julia.Tietze@med.uni-muenchen.de. 2. Department of Dermatology and Allergy, University Hospital Munich (LMU), Frauenlobstr. 9-11, 80337 Munich, Germany. 3. Department of Dermatology, School of Medicine, University of California, Davis, 3301 C Street, Sacramento, CA 95816, USA. 4. Department of Internal Medicine, University Hospital Munich (LMU), Ziemssenstr. 1, 80336 Munich, Germany.
Abstract
BACKGROUND: Immune checkpoint blockade (ICB) has been a breakthrough in the treatment of metastatic melanoma. But with only about 20-40% long-term responders and severe side-effects in about 12-17%, finding predictive markers for treatment response is of great interest. METHODS: We prospectively assessed clinical data, haematologic parameters and freshly isolated peripheral blood mononuclear cells of 30 patients treated with ipilimumab (n = 21) and pembrolizumab (n = 9) prior to the first 4 cycles with ICB and before the first tumour assessment. RESULTS: We discovered that the baseline levels of CD45RO+CD8+ T cells significantly differed among the patients. Thirteen (43%) of our patients had normal baseline levels of CD45RO+CD8+ T cells, whereas 17 (57%) patients were low on CD45RO+CD8+ T cells. The baseline levels of CD45RO+CD8+ T cells correlated significantly with the response to ipilimumab but not pembrolizumab. Patients with baseline levels of lower/equal 25% of CD45RO+CD8+ T cells did not respond to treatment with ipilimumab. Phenotyping the CD8+ T cells in patients treated with ipilimumab revealed an activated HLA-DR+CD25- phenotype, implying antigen non-specific stimulation. The levels of the HLA-DR+CD25-CD8+ T cells were significantly higher in patients with a normal baseline of CD45RO+CD8+ T cells and even increased significantly during treatment. Furthermore, proliferation of melanoma antigen recognized by T cells 1 (MART-1)-specific CD8+ T cells was not observed. Patients with normal baseline levels of CD45RO+CD8+ T cells showed a significant longer overall survival when treated with ipilimumab but not pembrolizumab. CONCLUSION: Patients with normal baseline levels of CD45RO+CD8+ T cells respond significantly more frequently to treatment with ipilimumab and the CD8+ T cells appear to be antigen non-specifically activated. The baseline level of CD45RO+CD8+ T cells represents a promising factor as biomarker for the prediction of the response to ipilimumab.
BACKGROUND: Immune checkpoint blockade (ICB) has been a breakthrough in the treatment of metastatic melanoma. But with only about 20-40% long-term responders and severe side-effects in about 12-17%, finding predictive markers for treatment response is of great interest. METHODS: We prospectively assessed clinical data, haematologic parameters and freshly isolated peripheral blood mononuclear cells of 30 patients treated with ipilimumab (n = 21) and pembrolizumab (n = 9) prior to the first 4 cycles with ICB and before the first tumour assessment. RESULTS: We discovered that the baseline levels of CD45RO+CD8+ T cells significantly differed among the patients. Thirteen (43%) of our patients had normal baseline levels of CD45RO+CD8+ T cells, whereas 17 (57%) patients were low on CD45RO+CD8+ T cells. The baseline levels of CD45RO+CD8+ T cells correlated significantly with the response to ipilimumab but not pembrolizumab. Patients with baseline levels of lower/equal 25% of CD45RO+CD8+ T cells did not respond to treatment with ipilimumab. Phenotyping the CD8+ T cells in patients treated with ipilimumab revealed an activated HLA-DR+CD25- phenotype, implying antigen non-specific stimulation. The levels of the HLA-DR+CD25-CD8+ T cells were significantly higher in patients with a normal baseline of CD45RO+CD8+ T cells and even increased significantly during treatment. Furthermore, proliferation of melanoma antigen recognized by T cells 1 (MART-1)-specific CD8+ T cells was not observed. Patients with normal baseline levels of CD45RO+CD8+ T cells showed a significant longer overall survival when treated with ipilimumab but not pembrolizumab. CONCLUSION:Patients with normal baseline levels of CD45RO+CD8+ T cells respond significantly more frequently to treatment with ipilimumab and the CD8+ T cells appear to be antigen non-specifically activated. The baseline level of CD45RO+CD8+ T cells represents a promising factor as biomarker for the prediction of the response to ipilimumab.
Authors: Quoc D Mac; Anirudh Sivakumar; Hathaichanok Phuengkham; Congmin Xu; James R Bowen; Fang-Yi Su; Samuel Z Stentz; Hyoungjun Sim; Adrian M Harris; Tonia T Li; Peng Qiu; Gabriel A Kwong Journal: Nat Biomed Eng Date: 2022-03-03 Impact factor: 29.234
Authors: Inna Smalley; Zhihua Chen; Manali Phadke; Jiannong Li; Xiaoqing Yu; Clayton Wyatt; Brittany Evernden; Jane L Messina; Amod Sarnaik; Vernon K Sondak; Chaomei Zhang; Vincent Law; Nam Tran; Arnold Etame; Robert J B Macaulay; Zeynep Eroglu; Peter A Forsyth; Paulo C Rodriguez; Y Ann Chen; Keiran S M Smalley Journal: Clin Cancer Res Date: 2021-05-25 Impact factor: 12.531
Authors: Aleksey K Molodtsov; Nikhil Khatwani; Jennifer L Vella; Kathryn A Lewis; Yanding Zhao; Jichang Han; Delaney E Sullivan; Tyler G Searles; Nicholas K Preiss; Tamer B Shabaneh; Peisheng Zhang; Aaron R Hawkes; Brian T Malik; Fred W Kolling; Edward J Usherwood; Sandra L Wong; Joseph D Phillips; Keisuke Shirai; Christina V Angeles; Shaofeng Yan; Tyler J Curiel; Yina H Huang; Chao Cheng; Mary Jo Turk Journal: Immunity Date: 2021-09-14 Impact factor: 43.474
Authors: Yue Lu; Alphonsus H C Ng; Frances E Chow; Richard G Everson; Beth A Helmink; Michael T Tetzlaff; Rohit Thakur; Jennifer A Wargo; Timothy F Cloughesy; Robert M Prins; James R Heath Journal: Nat Commun Date: 2021-06-29 Impact factor: 14.919